<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670030</url>
  </required_header>
  <id_info>
    <org_study_id>NET-001</org_study_id>
    <nct_id>NCT03670030</nct_id>
  </id_info>
  <brief_title>A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System</brief_title>
  <official_title>A Pilot Phase 2 Study of Albumin-bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Ramirez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ABI-009 will make advanced, malignant&#xD;
      neuroendocrine tumor(s) of the lung, gastrointestinal tract and/or pancreas that cannot be&#xD;
      removed by surgery smaller and slow the spread of your cancer in patients who have progressed&#xD;
      or been intolerant to everolimus. All eligible participants will receive ABI-009, the study&#xD;
      drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABI-009, human albumin-bound rapamycin, is an experimental drug. &quot;Experimental&quot; means that&#xD;
      the drug has not been approved by the Food and Drug Administration (FDA).&#xD;
&#xD;
      Rapamycin, the active part of the drug, inhibits a biological pathway (mTOR) that certain&#xD;
      cancers use to grow. Rapamycin and similar types of drugs have been used in many other&#xD;
      tumors, including advanced renal cell carcinoma. A standard mTOR inhibitor used in&#xD;
      neuroendocrine tumors is everolimus. The human albumin component of ABI-009 may allow&#xD;
      rapamycin to reach cancer cells more effectively.&#xD;
&#xD;
      ABI-009 has not been approved for the treatment of advanced, malignant neuroendocrine tumors&#xD;
      of the lung, gastrointestinal tract and/or pancreas. The information from this study might&#xD;
      help us identify if ABI-009 is safe and effective in this disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Actual">February 26, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate at 6 Months Per RECIST v1.1.</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate at 6 months is the proportion of patients who have partial or complete response or stable disease at 6 months.&#xD;
Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Experiencing Adverse Events</measure>
    <time_frame>Continuous from the signing of the informed consent to 28 days after last study treatment, on average 6 months</time_frame>
    <description>Percent of subjects with &gt;=5% adverse events or grades 3 or 4 adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009</intervention_name>
    <description>rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
    <arm_group_label>ABI-009</arm_group_label>
    <other_name>nab-rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Unresectable or metastatic patients with typical or atypical carcinoid tumors of the&#xD;
             lung or low or intermediate grade gastroenteropancreatic neuroendocrine tumors&#xD;
             (GEPNETs).&#xD;
&#xD;
          2. Patients must have measurable disease per RECIST 1.1.&#xD;
&#xD;
          3. Patients must have progressed on everolimus or been intolerant to everolimus.&#xD;
&#xD;
          4. Patients, ≥18 years old, must have Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Status 0 or 1.&#xD;
&#xD;
          5. Concurrent use of somatostatin analogs (SSAs) is allowed if currently used for symptom&#xD;
             control.&#xD;
&#xD;
          6. Adequate liver function:&#xD;
&#xD;
               1. Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN&#xD;
                  (&lt;5 x ULN if the patient has liver metastases).&#xD;
&#xD;
          7. Adequate renal function:&#xD;
&#xD;
             a. Serum creatinine ≤2 x ULN or creatinine clearance &gt;50 cc/hr (Cockroft-Gault).&#xD;
&#xD;
          8. Adequate biological parameters:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L&#xD;
&#xD;
               2. Platelet count ≥100,000/mm3 (100 × 109/L)&#xD;
&#xD;
               3. Hemoglobin ≥9 g/dL.&#xD;
&#xD;
          9. Fasting serum triglyceride ≤300 mg/dL; fasting serum cholesterol ≤350 mg/dL.&#xD;
&#xD;
         10. Male or non-pregnant and non-breast feeding female:&#xD;
&#xD;
               -  Females of child-bearing potential must agree to use effective contraception&#xD;
                  without interruption from 28 days prior to starting investigational product (IP)&#xD;
                  throughout 3 months after last dose of IP and have a negative serum pregnancy&#xD;
                  test (β-hCG) result at screening and agree to ongoing pregnancy testing during&#xD;
                  the course of the study, and after the end of study treatment. A second form of&#xD;
                  birth control is required even if she has had a tubal ligation.&#xD;
&#xD;
               -  Male patients must practice abstinence or agree to use a condom during sexual&#xD;
                  contact with a pregnant female or a female of childbearing potential while&#xD;
                  participating in the study and throughout 3 months after last dose of IP. A&#xD;
                  second form of birth control is required even if he has undergone a successful&#xD;
                  vasectomy.&#xD;
&#xD;
         11. Life expectancy of &gt;3 months, as determined by the investigator.&#xD;
&#xD;
         12. Ability to understand and sign informed consent.&#xD;
&#xD;
         13. Willingness and ability to comply with scheduled visits, laboratory tests, and other&#xD;
             study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients currently undergoing anti-cancer therapy for neuroendocrine tumors (other&#xD;
             than SSAs for symptoms).&#xD;
&#xD;
          2. History of allergic reactions to compounds of similar chemical or biologic composition&#xD;
             to ABI-009.&#xD;
&#xD;
          3. Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A&#xD;
             patient with controlled and asymptomatic CNS metastases may participate in this study.&#xD;
             As such, the patient must have completed any prior treatment for CNS metastases ?28&#xD;
             days (including radiotherapy and/or surgery) prior to start of treatment in this study&#xD;
             and should not be receiving chronic corticosteroid therapy for the CNS metastases.&#xD;
&#xD;
          4. Active gastrointestinal bleeding.&#xD;
&#xD;
          5. Uncontrolled serious medical or psychiatric illness. Patients with a &quot;currently&#xD;
             active&quot; second malignancy other than non-melanoma skin cancers, carcinoma in situ of&#xD;
             the cervix, resected incidental prostate cancer (staged pathological tumor-2 (pT2)&#xD;
             with Gleason Score ≤6 and postoperative prostate-specific antigen (PSA) &lt;0.5 ng/mL),&#xD;
             or other adequately treated carcinoma-in-situ are ineligible. Patients are not&#xD;
             considered to have a &quot;currently active&quot; malignancy if they have completed therapy and&#xD;
             are free of disease for ≥1 year).&#xD;
&#xD;
          6. Recent infection requiring systemic anti-infective treatment that was completed ≤14&#xD;
             days prior to enrollment (with the exception of uncomplicated urinary tract infection&#xD;
             or upper respiratory tract infection).&#xD;
&#xD;
          7. Uncontrolled diabetes mellitus as defined by HbA1c &gt;8% despite adequate therapy.&#xD;
&#xD;
          8. Unstable coronary artery disease or myocardial infarction during preceding 6 months.&#xD;
&#xD;
          9. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary&#xD;
             hypertension.&#xD;
&#xD;
         10. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving&#xD;
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with&#xD;
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,&#xD;
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to&#xD;
             receiving the first dose of ABI-009.&#xD;
&#xD;
         11. Known Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
         12. Known active Hepatitis B or Hepatitis C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ramirez, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ochnser Clinic Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>May 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2021</results_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Robert Ramirez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregate data will be made publicly available in the form of poster presentations or journal articles.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03670030/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03670030/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABI-009</title>
          <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.&#xD;
ABI-009: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABI-009</title>
          <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.&#xD;
ABI-009: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="51" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Control Rate at 6 Months Per RECIST v1.1.</title>
        <description>Disease control rate at 6 months is the proportion of patients who have partial or complete response or stable disease at 6 months.&#xD;
Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABI-009</title>
            <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.&#xD;
ABI-009: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate at 6 Months Per RECIST v1.1.</title>
          <description>Disease control rate at 6 months is the proportion of patients who have partial or complete response or stable disease at 6 months.&#xD;
Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Experiencing Adverse Events</title>
        <description>Percent of subjects with &gt;=5% adverse events or grades 3 or 4 adverse events</description>
        <time_frame>Continuous from the signing of the informed consent to 28 days after last study treatment, on average 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABI-009</title>
            <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.&#xD;
ABI-009: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Experiencing Adverse Events</title>
          <description>Percent of subjects with &gt;=5% adverse events or grades 3 or 4 adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Continuous from the signing of the informed consent to 28 days after last study treatment, on average 6 months</time_frame>
      <desc>Percent of subjects with &gt;=5% adverse events or grades 3 or 4 adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>ABI-009</title>
          <description>In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.&#xD;
ABI-009: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <counts group_id="E1" events="25" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers affecting usefulness interpreting results. Only 2 patients were eligible for analysis of primary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Ramirez, DO</name_or_title>
      <organization>Ochsner Medical Center</organization>
      <phone>504-464-8500</phone>
      <email>awendt@ochsner.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

